While we don't yet know the financial details of this partnership, I'm projecting that the BioTime/LifeMap share of revenues will be revealed to be significant. There are really three aspects to creating such a report. One, obviously, is the physical process of genome sequencing. The second is the correlation of individual genomic information with the database of current scientific knowledge, which is what LifeMap contributes. The third is the data mining and report generation. If BioTime/LifeMap doesn't get around a third of revenues generated per report, I would be very surprised -- but that information will come out in time.
How big is the genomic interpretation business? BioTime cites this report by United Healthcare, which estimates that American spending on genetic testing and molecular diagnostics is $3-4 billion annually. Obviously, this number will grow as these processes become easier and more useful.
It's "amazing" all right..to anybody who thinks that "a third" has anything to do with anything.
If you wanted to learn some highschool senior level due diligence skills, you could google: "Licensing the GATK" and make some phone calls.